Company and Partner News
XOMA raises up to $140M with Blue Owl Capital
“The Blue Owl financing provides us with significant non-dilutive capital to drive shareholder value through stock repurchases and additional royalty and milestone acquisitions,” stated Brad Sitko, Chief Investment Officer of XOMA.
2023 Letter to Shareholders
Since joining the Company in January 2023 as Executive Chairman and interim CEO, I have come to better appreciate the opportunity presented by XOMA’s unique business model and seasoned team, and equally important, the optionality embedded within our growing royalty and milestone portfolio.
Chairman’s 2022 Year-end Letter
As 2022 comes to an end and my retirement begins, I take this opportunity to ask you to look forward and see what I see – XOMA, the Royalty Aggregator for biotech companies.
Press Releases
-
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
-
XOMA Corporation Announces Closing of Tender Offer
April 3, 2024
-
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024